PLoS ONE (May 2008)

Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.

  • Yanan Yang,
  • Kentaro Iwanaga,
  • Maria Gabriela Raso,
  • Marie Wislez,
  • Amy E Hanna,
  • Eric D Wieder,
  • Jeffrey J Molldrem,
  • Ignacio I Wistuba,
  • Garth Powis,
  • Francesco J Demayo,
  • Carla F Kim,
  • Jonathan M Kurie

DOI
https://doi.org/10.1371/journal.pone.0002220
Journal volume & issue
Vol. 3, no. 5
p. e2220

Abstract

Read online

Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in Western countries. Developing more effective NSCLC therapeutics will require the elucidation of the genetic and biochemical bases for this disease. Bronchioalveolar stem cells (BASCs) are a putative cancer stem cell population in mouse models of oncogenic K-ras-induced lung adenocarcinoma, an histologic subtype of NSCLC. The signals activated by oncogenic K-ras that mediate BASC expansion have not been fully defined.We used genetic and pharmacologic approaches to modulate the activity of phosphatidylinositol 3-kinase (PI3K), a key mediator of oncogenic K-ras, in two genetic mouse models of lung adenocarcinoma. Oncogenic K-ras-induced BASC accumulation and tumor growth were blocked by treatment with a small molecule PI3K inhibitor and enhanced by inactivation of phosphatase and tensin homologue deleted from chromosome 10, a negative regulator of PI3K.We conclude that PI3K is a critical regulator of BASC expansion, supporting treatment strategies to target PI3K in NSCLC patients.